進んだ胆管がんにおけるセカンドライン化学療法療法の比較:体系的レビュー,メタ解析,および集団ベースのコホート研究
Galam Leem1,2, Kihun Kim3, Jeehoon Kim1,2
1Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
International journal of surgery (London, England)
|September 5, 2025
まとめ
FOLFIRINOXは,進行性胆道がんのセカンドライン治療として有望な結果を示しており,他の治療法と比較して生存率が向上しています. この化学療法の組み合わせは管理可能な副作用があり,BTC治療の潜在的使用を支持しています.
科学分野:
- 腫瘍学
- 胃腸内科
- 臨床薬理学
背景:
- 胆管がん (BTC) は攻撃的であり,治療の選択肢は限られている.
- BTCにおける第一線化学療法の失敗は,効果的な第二線戦略を必要とします.
- 第二線BTC治療におけるFOLFIRINOXの役割については,さらなる説明が必要である.
研究 の 目的:
- 高度なBTCのセカンドライン療法としてのFOLFIRINOXの有効性と安全性を評価する.
- FOLFIRINOXと既存のセカンドライン療法 (FOLFIRI,FOLFOX,nal- IRI/ FL) をメタ分析で比較する.
主な方法:
- FOLFIRINOXで治療された54人の進行性BTC患者の遡及分析.
- 二次線BTC治療に関する21の研究の体系的レビューとメタ解析
- 無進行生存率 (PFS),全生存率 (OS),客観的応答率 (ORR),疾病制御率 (DCR) および安全性の評価
主要な成果:
- コホートでは,PFSの中央値は2. 7ヶ月,OSは8. 9ヶ月でした.
- メタアナリシスは,FOLFIRINOXの合計PFSが4. 15ヶ月とOSが8. 91ヶ月であることを示した.
- 3〜5度の中性無血症は,患者の40. 7%で,管理可能な毒性および低減率で発生した.
結論:
- FOLFIRINOXは,先進的なBTCの現在のセカンドライン療法と比較して,数値的に優れた結果を示しています.
- 管理可能な毒性は,FOLFIRINOXを潜在的なセカンドライン治療の選択肢として支持しています.
- これらの発見を検証し,患者の選択を洗練するためにさらなる研究が必要である.
関連する概念動画
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259


